Contact Us
Posted: November 7, 2017
  • Company News

Abingdon Health and Innova Biosciences sign agreement

Abingdon Health and Innova Biosciences, a SYGNIS company, form co-marketing agreement

Abingdon Health Limited (“Abingdon”), York UK and Innova Biosciences Ltd (now known as Expedeon), a SYGNIS company, Cambridge UK (“Innova”) announce a co-marketing agreement to work in partnership on the provision of development and manufacturing services to contract customers.

Under the terms of the agreement, Abingdon Health will be Innova’s preferred supplier for the provision of lateral flow contract manufacturing and reader development and manufacturing. In addition, Innova will be Abingdon Health’s preferred partner for the supply of colloidal gold and other conjugation products. Both parties will work collaboratively to provide customers with integrated lateral flow assay and reader development solutions.

About Abingdon Health

Abingdon provides lateral flow assay and reader development and manufacturing services for customers looking to develop new assays or looking to transfer existing laboratory-based assays to a lateral flow format. Abingdon take projects from initial concept all the way through to routine and large-scale manufacturing and also offers routine manufacturing services for customers looking to transfer a lateral flow test already in routine manufacture to new lateral flow manufacturing partners.

Abingdon’s lateral flow reader, the ADxLR5®, is CE marked and FDA registered and can be fully customised to meet the needs of clients looking for a quantitative solution for a lateral flow assay.

About Innova Biosciences (now known as Expedeon) , a SYGNIS company

Innova Biosciences, a SYGNIS company, are world leading experts in easy-to-use, cutting-edge bioconjugation technologies and services. The Company has the flexibility to support scientists from academia through to commercial manufacturing, developing and supplying reagent products to make science easier, both off-the-shelf and to customer specification. Innova’s products are based on its antibody and protein labelling technology, nanoparticle and oligonucleotide labelling and phosphate detection enzyme assay technologies.

Commenting on the Agreement:

Chris Yates, CEO of Abingdon Health said:

“Both Abingdon and Innova place a great deal of emphasis on innovation and customer service and therefore we are pleased to combine our capabilities to provide customers with an integrated end-to-end solution to the development and manufacture of lateral flow assays and readers.”

Alastair Carrington, VP of Business Development & Marketing at Innova Biosciences, a SYGNIS company, commented:

“Innova is very pleased to collaborate with Abingdon, to be their preferred supplier for colloidal gold and innovative conjugation products. By combining Innova’s early stage lateral flow assay R&D expertise with Abingdon’s manufacturing and reader capabilities, we believe we are set to deliver the best results for our respective customers.”